03.06.2013 Views

Registration Document 2005 - Total.com

Registration Document 2005 - Total.com

Registration Document 2005 - Total.com

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Note 32.6: IFRS restatements with an impact<br />

on the net in<strong>com</strong>e<br />

Note 32.6a: Amortization of goodwill<br />

Pursuant to IFRS 3 “Business <strong>com</strong>binations”, goodwill is no longer<br />

amortized. Instead, it is tested for impairment annually. The impact<br />

on 2004 net in<strong>com</strong>e is 161 million euros, due to the cancellation of<br />

goodwill amortization.<br />

Note 32.6b: Share-based payments<br />

The Group applies IFRS 2 “Share-based payments” as published<br />

by the International Accounting Standards Board (IASB).<br />

This standard applies to employee stock-option and share<br />

purchase plans and to capital increases reserved for employees<br />

retrospectively and not solely to the share transactions that were<br />

granted after November 7, 2002.<br />

These employee benefits are recognized as expenses with a<br />

corresponding credit to shareholders’ equity.<br />

The cost of options is valued according to the Black & Scholes<br />

method and allocated on a straight-line basis between the grant<br />

date and vesting date. For employee-reserved capital increases, the<br />

cost is immediately recognized as an expense.<br />

The 2004 net in<strong>com</strong>e is adjusted due to an expense relating to<br />

employee share option and purchase plans and to the employeereserved<br />

capital increase in 2003. The corresponding charge is<br />

estimated at approximately 138 million euros.<br />

Appendix 1 – Consolidated financial statements<br />

Notes to the consolidated financial statements 9<br />

Note 32.6c: Equity-method affiliates’ IFRS restatement<br />

This restatement primarily relates to the implementation of IFRS<br />

in the equity-method affiliates’ financial statements, Sanofi-Aventis<br />

and Cepsa.<br />

Within the financial statements prepared in <strong>com</strong>pliance with IFRS<br />

by Sanofi-Aventis, in-progress R&D costs of Aventis have been<br />

capitalized as at the date of the merger. According to French GAAP,<br />

the R&D costs were directly charged to expense. The impact of<br />

this restatement amounts to 746 million euros on the net in<strong>com</strong>e<br />

– Group share.<br />

The effect on net in<strong>com</strong>e of IFRS restatements related to<br />

inventories and share-based payments, as indicated previously,<br />

may change in the future depending on the volatility in prices of raw<br />

materials and specific provisions included within employee share<br />

purchase or option plans, respectively.<br />

TOTAL - <strong>Registration</strong> <strong>Document</strong> <strong>2005</strong><br />

223

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!